NPXe is a late clinical-state pharmaceutical and drug delivery device company developing pharmaceutical grade xenon gas for inhalation to treat Post Cardiac Arrest Syndrome (PCAS). This post-cardiac condition is characterized by a range of complications principally to the brain and the heart from the sudden loss of blood flow (“ischaemia”) as well as the subsequent reconstitution of blood flow (“reperfusion”) following successful resuscitation. There is currently no approved pharmacotherapy for neuroprotection in this patient population.
Recently, a positive Phase II clinical trial demonstrated a statistically significant reduction in brain tissue damage and a trend towards better survival outcomes in PCAS resulting from an Out of Hospital Cardiac Arrest (“OHCA”). (Results published in the Journal of the American Medical Association-, March 2016: PMID 26978207).
NPXe is currently initiating a pivotal Phase III clinical trial with XENEX™ for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest (XePOHCAS).
NPXe Limited, the parent company of the NPXe group, was incorporated and registered in England and Wales. The NPXe group consists of three wholly owned subsidiaries, with operations in the following locations:
- Neuroprotexeon Limited, UK
- Neuroprotexeon Inc., US
- Neuroprotexeon GmbH, Germany
- Maze, Mervyn. Preclinical neuroprotective actions of xenon and possible implications for human therapeutics: a narrative review. Canadian Journal of Anesthesia/ Journal canadien d'anesthésie Feb. 2016, 63, Issue 2, pp 212–226.
- Laitio R, Hynninen M, Arola O, Virtanen S, Parkkola R, Saunavaara J, Roine RO, Gronlund J, Ylikoski E, Wennervirta J, Backlund M, Silvasti P, Nukarinen E, Tiainen M, Saraste A, Pietila M, Airaksinen J, Valanne L, Martola J, Silvennoinen H, Scheinin H, Harjola VP, Niiranen J, Korpi K, Varpula M, Inkinen O, Olkkola KT, Maze M, Vahlberg T, Laitio T, (2016) Effect of Inhaled Xenon on Cerebral White Matter Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA 315: 1120-1128.